Indian Journal of Experimental Biology 2011-11-01

Inhibition of angiogenic attributes by decursin in endothelial cells and ex vivo rat aortic ring angiogenesis model.

Tariq A Bhat, Jung S Moon, Sookyeon Lee, Dongsool Yim, Rana P Singh

Index: Indian J. Exp. Biol. 49(11) , 848-56, (2011)

Full Text: HTML

Abstract

The present study was undertaken to observe the inhibition of angiogenesis by decursin. It was the first time to show that decursin offered strong anti-angiogenic activities under the biologically relevant growth (with serum) conditions. Decursin significantly inhibited human umbilical vein endothelial cell (HUVEC) proliferation concomitant with G1 phase cell cycle arrest. Decursin also inhibited HUVEC-capillary tube formation and invasion/migration in a dose-dependant manner which was associated with the suppression of matrix metalloproteinase (MMP) -2 and -9 activities. Decursin suppressed angiogenesis in ex vivo rat aortic ring angiogenesis model where it significantly inhibited blood capillary-network sprouting from rat aortic sections. Taken together, these findings suggested anti-angiogenic activity of decursin in biologically relevant condition, and warrants further pre-clinical studies for its potential clinical usefulness.


Related Compounds

Related Articles:

Decursin attenuates hepatic fibrogenesis through interrupting TGF-beta-mediated NAD(P)H oxidase activation and Smad signaling in vivo and in vitro.

2014-07-17

[Life Sci. 108(2) , 94-103, (2014)]

Ultrafine Angelica gigas powder normalizes ovarian hormone levels and has antiosteoporosis properties in ovariectomized rats: particle size effect.

2012-10-01

[J. Med. Food 15(10) , 863-72, (2012)]

Decursin exerts anti-cancer activity in MDA-MB-231 breast cancer cells via inhibition of the Pin1 activity and enhancement of the Pin1/p53 association.

2014-02-01

[Phytother Res. 28(2) , 238-44, (2014)]

Biopharmaceutical characterization of decursin and their derivatives for drug discovery.

2013-10-01

[Drug Dev. Ind. Pharm. 39(10) , 1523-30, (2013)]

A novel derivative of decursin, CSL-32, blocks migration and production of inflammatory mediators and modulates PI3K and NF-κB activities in HT1080 cells.

2012-07-01

[Cell Biol. Int. 36(7) , 683-8, (2012)]

More Articles...